Longeveron to Present at the 2021 Dawson James Securities 6th Annual Small Cap Growth Conference
October 14 2021 - 8:00AM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a
clinical stage biotechnology company developing cellular therapies
for chronic, aging-related and life-threatening conditions,
announced today that Geoff Green, Chief Executive Officer of
Longeveron, will present at the Dawson James Small Cap Growth
Conference on Thursday, October 21, 2021 at 11:25 a.m. ET in
Jupiter, Florida.
A live webcast of the presentation will be
available via the Investors & Media section of the Company
website. Following the live webcast, an archived replay of the
webcast will be available on the website.
Longeveron management will be conducting 1x1
meetings during the conference. To schedule a meeting, please
visit Dawson James Small Cap Growth Conference.
Dawson James’ flagship Small Cap Growth
Conference will bring together senior executives from approximately
40 small-cap growth companies operating at the forefront of the
healthcare, technology and consumer sectors. The conference brings
together institutional funds, family offices and high-net-worth
accredited investors. For more information on the conference and
how to register, please visit https://dawsonjames.com/.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology
company developing cellular therapies for specific aging-related
and life-threatening conditions. The Company’s lead investigational
product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”),
which is derived from culture-expanded medicinal signaling cells
(MSCs) that are sourced from bone marrow of young, healthy adult
donors. Longeveron believes that by using the same cells that
promote tissue repair, organ maintenance, and immune system
function, it can develop safe and effective therapies for some of
the most difficult disorders associated with the aging process and
other medical disorders. Longeveron is currently sponsoring Phase 1
and 2 clinical trials in the following indications: Aging Frailty,
Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory
Distress Syndrome (ARDS), and hypoplastic left heart syndrome
(HLHS). The Company’s mission is to advance Lomecel-B and other
cell-based product candidates into pivotal Phase 3 trials, with the
goal of achieving regulatory approvals, subsequent
commercialization and broad use by the healthcare community.
Additional information about the Company is available at
www.longeveron.com.
Investor Contact:
Brendan PayneStern Investor RelationsOffice
Direct: 212-698-8695 |Office Main:
212-362-1200brendan.payne@sternir.com | www.sternir.com
Source: Longeveron IncSource: LGVN
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jul 2023 to Jul 2024